CN114924073A - 结直肠进展期肿瘤诊断标志物组合及其应用 - Google Patents
结直肠进展期肿瘤诊断标志物组合及其应用 Download PDFInfo
- Publication number
- CN114924073A CN114924073A CN202210317138.9A CN202210317138A CN114924073A CN 114924073 A CN114924073 A CN 114924073A CN 202210317138 A CN202210317138 A CN 202210317138A CN 114924073 A CN114924073 A CN 114924073A
- Authority
- CN
- China
- Prior art keywords
- acid
- colorectal
- metabolic marker
- beta
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 99
- 238000003745 diagnosis Methods 0.000 title claims abstract description 66
- 239000003550 marker Substances 0.000 title claims abstract description 48
- 230000002503 metabolic effect Effects 0.000 claims abstract description 61
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims abstract description 60
- GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 claims abstract description 54
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims abstract description 52
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 48
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 48
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 44
- DGABKXLVXPYZII-MMTMODRTSA-N Isohyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-MMTMODRTSA-N 0.000 claims abstract description 41
- VXUOFDJKYGDUJI-OAQYLSRUSA-N 1-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-OAQYLSRUSA-N 0.000 claims abstract description 40
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 39
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 36
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 36
- 229960000367 inositol Drugs 0.000 claims abstract description 36
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims abstract description 33
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims abstract description 33
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 31
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims abstract description 31
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 30
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims abstract description 30
- KXGVEGMKQFWNSR-OFYXWCICSA-N 3beta,12alpha-dihydroxy-5beta-cholan-24-oic acid Chemical group C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-OFYXWCICSA-N 0.000 claims abstract description 29
- ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 claims abstract description 28
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims abstract description 28
- BGOJKUCHTMYINI-DTLRTWKJSA-N (5Z,8Z,11Z,14Z)-icosatetraenedioic acid Chemical compound OC(=O)CCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O BGOJKUCHTMYINI-DTLRTWKJSA-N 0.000 claims abstract description 27
- 229930185560 Pseudouridine Natural products 0.000 claims abstract description 27
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims abstract description 27
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims abstract description 27
- LMHJFKYQYDSOQO-UHFFFAOYSA-N hydroxydecanoic acid Natural products CCCCCC(O)CCCC(O)=O LMHJFKYQYDSOQO-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 27
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims abstract description 27
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims abstract description 26
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims abstract description 26
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 26
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims abstract description 26
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims abstract description 26
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims abstract description 26
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 26
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 24
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 24
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004220 glutamic acid Substances 0.000 claims abstract description 23
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 23
- 229960004295 valine Drugs 0.000 claims abstract description 22
- 239000004380 Cholic acid Substances 0.000 claims abstract description 21
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 claims abstract description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 21
- 229960002471 cholic acid Drugs 0.000 claims abstract description 21
- 108010050848 glycylleucine Proteins 0.000 claims abstract description 21
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- KTFMPDDJYRFWQE-DDWIOCJRSA-N (3r)-3-propanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride Chemical compound [Cl-].CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C KTFMPDDJYRFWQE-DDWIOCJRSA-N 0.000 claims abstract description 20
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 20
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 20
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 20
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 claims abstract description 20
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 17
- 239000002207 metabolite Substances 0.000 claims description 97
- 238000012544 monitoring process Methods 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- HSNPMXROZIQAQD-GBURMNQMSA-N taurolithocholic acid sulfate Chemical compound C([C@H]1CC2)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 HSNPMXROZIQAQD-GBURMNQMSA-N 0.000 claims description 6
- 239000001384 succinic acid Substances 0.000 claims description 4
- LKTXOQJJFLAZRW-XVBIMYNNSA-N taurocholic acid 3-sulfate Chemical compound C([C@H]1C[C@H]2O)[C@H](OS(O)(=O)=O)CC[C@]1(C)C1C2C2CCC([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 LKTXOQJJFLAZRW-XVBIMYNNSA-N 0.000 claims 3
- 239000004395 L-leucine Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 81
- 206010009944 Colon cancer Diseases 0.000 abstract description 78
- 208000003200 Adenoma Diseases 0.000 abstract description 50
- 206010001233 Adenoma benign Diseases 0.000 abstract description 38
- 230000035945 sensitivity Effects 0.000 abstract description 11
- LKTXOQJJFLAZRW-HZAMXZRMSA-N Taurocholic acid 3-sulfate Chemical compound C([C@H]1C[C@H]2O)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 LKTXOQJJFLAZRW-HZAMXZRMSA-N 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000000523 sample Substances 0.000 description 65
- 210000002381 plasma Anatomy 0.000 description 51
- 238000001514 detection method Methods 0.000 description 50
- 238000004458 analytical method Methods 0.000 description 32
- 230000000750 progressive effect Effects 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 239000000126 substance Substances 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 230000004060 metabolic process Effects 0.000 description 18
- 238000010276 construction Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 16
- 230000002250 progressing effect Effects 0.000 description 13
- -1 propionyl levocarnitine hydrochloride Chemical compound 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- AKVBCGQVQXPRLD-ZETCQYMHSA-N (2s)-2-azaniumyloctanoate Chemical compound CCCCCC[C@H]([NH3+])C([O-])=O AKVBCGQVQXPRLD-ZETCQYMHSA-N 0.000 description 9
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 9
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 9
- 229940114079 arachidonic acid Drugs 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 9
- 238000003759 clinical diagnosis Methods 0.000 description 8
- 238000007477 logistic regression Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010007979 Glycocholic Acid Proteins 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- 229930064664 L-arginine Natural products 0.000 description 7
- 235000014852 L-arginine Nutrition 0.000 description 7
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 7
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 7
- 229940099347 glycocholic acid Drugs 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- JKFYKCYQEWQPTM-ZETCQYMHSA-N (2s)-2-amino-2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-ZETCQYMHSA-N 0.000 description 4
- LCPDWSOZIOUXRV-RALIUCGRSA-N 2-(2,3,4,5,6-pentadeuteriophenoxy)acetic acid Chemical compound [2H]C1=C([2H])C([2H])=C(OCC(O)=O)C([2H])=C1[2H] LCPDWSOZIOUXRV-RALIUCGRSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000002052 colonoscopy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 229960000243 levocarnitine hydrochloride Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QIAFMBKCNZACKA-VLDREHNRSA-N 2,2-dideuterio-2-[deuterio-(2,3-dideuteriobenzoyl)amino]acetic acid Chemical compound OC(=O)C([2H])([2H])N([2H])C(=O)C1=CC=CC([2H])=C1[2H] QIAFMBKCNZACKA-VLDREHNRSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004451 qualitative analysis Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005315 distribution function Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- FKKCPZSMQFVXFV-UHFFFAOYSA-N phosphonooxymethyl dihydrogen phosphate Chemical compound OP(O)(=O)OCOP(O)(O)=O FKKCPZSMQFVXFV-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010863 targeted diagnosis Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007884 metabolite profiling Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
Description
名称 | 型号 | 品牌 |
HPLC-MS/MS | QTRAP 6500+ | SCIEX |
HPLC-TOF-MS | TripleTOF 6600 | SCIEX |
离心机 | 5424R | Eppendorf |
离心浓缩仪 | CentriVap | LABCONCO |
涡旋混合器 | VORTEX-5 | Kyllin-Be11 |
化合物 | CAS编号 | 品牌 |
L-2-苯丙氨酸 | 103616-89-3 | 百灵威 |
[2H3]-L-肉碱-d3盐酸盐 | 350818-62-1 | isoreag |
4-氟-L-2-苯基甘氨酸 | 19883-57-9 | TCI |
L-苯基丙氨酸 | 63-91-2 | isoreag |
[2H5]-马尿酸 | 53518-98-2 | isoreag |
[2H5]-犬尿酸 | 350820-13-2 | isoreag |
[2H5]-苯氧基乙酸 | 154492-74-7 | isoreag |
甲醇 | 67-56-1 | Merck |
乙腈 | 75-05-8 | Merck |
乙酸 | 64-19-7 | Aladdin |
编号 | 中文名称 | AUC | 灵敏度 | 特异性 |
1 | 3β-脱氧胆酸 | 0.823 | 79.70% | 80.80% |
2 | 溶血磷脂酰乙醇胺(P-18:0) | 0.814 | 78.50% | 79.70% |
3 | 石胆酸 | 0.806 | 77.60% | 79.00% |
4 | DL-2-氨基辛酸 | 0.797 | 76.80% | 78.50% |
5 | 3β-猪去氧胆酸 | 0.795 | 76.40% | 78.30% |
6 | 溶血磷脂酰胆碱(14:0) | 0.785 | 76.20% | 77.90% |
7 | 肌醇 | 0.776 | 75.90% | 77.40% |
8 | 谷氨酸 | 0.765 | 74.00% | 76.30% |
9 | 假尿苷 | 0.757 | 73.10% | 75.40% |
10 | 丙酰左旋肉碱盐酸盐 | 0.754 | 72.90% | 74.90% |
11 | 4-氨基丁酸 | 0.748 | 72.60% | 74.50% |
12 | 羟基癸酸 | 0.742 | 72.20% | 74.10% |
13 | 20-羧基花生四烯酸 | 0.736 | 72.10% | 73.90% |
14 | L-焦谷氨酸 | 0.731 | 71.90% | 73.40% |
15 | 顺式-4-羟基-L-脯氨酸 | 0.729 | 71.80% | 73.30% |
16 | 对称N,N-二甲基精氨酸 | 0.727 | 71.70% | 73.10% |
17 | S-腺苷同型半胱氨酸 | 0.726 | 71.50% | 72.90% |
18 | α-亚麻酸 | 0.723 | 71.30% | 72.40% |
19 | 马尿酸 | 0.721 | 71.20% | 72.20% |
20 | 甘氨酰-L-亮氨酸 | 0.719 | 71.00% | 72.00% |
21 | 12-羟基二十碳四烯酸 | 0.716 | 70.70% | 71.60% |
22 | L-缬氨酸 | 0.713 | 70.40% | 71.40% |
23 | 琥珀酸 | 0.711 | 70.20% | 71.00% |
24 | 不对称二甲基精氨酸 | 0.710 | 70.10% | 70.60% |
25 | 牛磺石胆酸-3-硫酸盐 | 0.709 | 69.90% | 70.40% |
26 | 甘氨石胆酸 | 0.706 | 69.70% | 70.00% |
27 | γ-鼠胆酸 | 0.703 | 69.50% | 69.90% |
28 | DL-Β-苯乳酸 | 0.702 | 69.40% | 69.90% |
29 | 鹅脱氧胆酸 | 0.703 | 69.30% | 69.80% |
中文名称 | 差异倍数 | P value |
3β-脱氧胆酸 | 0.55 | 4.09E-04 |
石胆酸 | 0.62 | 8.77E-06 |
溶血磷脂酰胆碱(14:0) | 0.65 | 2.04E-08 |
DL-2-氨基辛酸 | 0.73 | 2.33E-03 |
3β-猪去氧胆酸 | 0.79 | 6.85E-04 |
肌醇 | 0.82 | 7.64E-04 |
谷氨酸 | 1.48 | 7.78E-03 |
假尿苷 | 1.16 | 2.03E-02 |
丙酰左旋肉碱盐酸盐 | 0.85 | 9.78E-03 |
顺式-4-羟基-L-脯氨酸 | 0.80 | 3.23E-02 |
对称N,N-二甲基精氨酸 | 1.12 | 7.39E-03 |
S-腺苷同型半胱氨酸 | 1.17 | 3.77E-02 |
α-亚麻酸 | 1.28 | 1.66E-02 |
马尿酸 | 0.89 | 3.55E-02 |
中文名称 | 差异倍数 | P value |
溶血磷脂酰乙醇胺(P-18:0) | 0.80 | 6.37E-03 |
肌醇 | 0.88 | 2.79E-02 |
4-氨基丁酸 | 1.46 | 2.85E-03 |
L-焦谷氨酸 | 1.35 | 2.11E-04 |
S-腺苷同型半胱氨酸 | 1.11 | 6.42E-03 |
不对称二甲基精氨酸 | 1.06 | 9.24E-03 |
牛磺石胆酸-3-硫酸盐 | 0.81 | 2.79E-02 |
中文名称 | 差异倍数 | P value |
溶血磷脂酰乙醇胺(P-18:0) | 0.78 | 9.58E-07 |
马尿酸 | 0.65 | 1.96E-02 |
甘氨酰-L-亮氨酸 | 0.95 | 2.19E-02 |
12-羟基二十碳四烯酸 | 0.75 | 1.24E-04 |
琥珀酸 | 1.54 | 1.71E-03 |
不对称二甲基精氨酸 | 1.07 | 6.06E-03 |
甘氨石胆酸 | 0.57 | 1.40E-02 |
γ-鼠胆酸 | 2.74 | 2.15E-02 |
编号 | 中文名称 | AUC | 灵敏度 | 特异性 |
1 | 石胆酸 | 0.828 | 80.50% | 81.70% |
2 | 3β-脱氧胆酸 | 0.817 | 79.30% | 80.60% |
3 | 溶血磷脂酰乙醇胺(P-18:0) | 0.810 | 78.30% | 80.00% |
4 | 3β-猪去氧胆酸 | 0.803 | 77.60% | 79.40% |
5 | DL-2-氨基辛酸 | 0.798 | 77.30% | 79.10% |
6 | 溶血磷脂酰胆碱(14:0) | 0.796 | 77.00% | 78.80% |
7 | 肌醇 | 0.791 | 76.70% | 78.30% |
8 | 谷氨酸 | 0.785 | 75.70% | 77.60% |
9 | 4-氨基丁酸 | 0.778 | 75.00% | 77.00% |
10 | 丙酰左旋肉碱盐酸盐 | 0.771 | 74.50% | 76.30% |
11 | 假尿苷 | 0.766 | 74.10% | 75.80% |
12 | 羟基癸酸 | 0.761 | 73.50% | 75.30% |
13 | L-焦谷氨酸 | 0.753 | 72.90% | 74.80% |
14 | 20-羧基花生四烯酸 | 0.745 | 72.70% | 74.30% |
15 | 对称N,N-二甲基精氨酸 | 0.744 | 72.60% | 74.20% |
16 | 顺式-4-羟基-L-脯氨酸 | 0.742 | 72.50% | 74.00% |
17 | S-腺苷同型半胱氨酸 | 0.741 | 72.30% | 73.80% |
18 | 马尿酸 | 0.738 | 72.10% | 73.30% |
19 | α-亚麻酸 | 0.737 | 72.00% | 73.10% |
20 | 甘氨酰-L-亮氨酸 | 0.735 | 71.80% | 72.90% |
21 | L-缬氨酸 | 0.733 | 71.50% | 72.50% |
22 | 12-羟基二十碳四烯酸 | 0.732 | 71.20% | 72.30% |
23 | 琥珀酸 | 0.729 | 71.00% | 71.90% |
24 | 不对称二甲基精氨酸 | 0.727 | 70.90% | 71.50% |
25 | γ-鼠胆酸 | 0.726 | 70.70% | 71.30% |
26 | 甘氨石胆酸 | 0.724 | 70.50% | 70.90% |
27 | 牛磺石胆酸-3-硫酸盐 | 0.723 | 70.30% | 70.80% |
28 | 鹅脱氧胆酸 | 0.720 | 70.20% | 70.80% |
29 | DL-Β-苯乳酸 | 0.718 | 70.10% | 70.70% |
Claims (14)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210317138.9A CN114924073B (zh) | 2022-03-28 | 2022-03-28 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
PCT/CN2023/084000 WO2023185709A1 (zh) | 2022-03-28 | 2023-03-27 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210317138.9A CN114924073B (zh) | 2022-03-28 | 2022-03-28 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114924073A true CN114924073A (zh) | 2022-08-19 |
CN114924073B CN114924073B (zh) | 2023-12-01 |
Family
ID=82804968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210317138.9A Active CN114924073B (zh) | 2022-03-28 | 2022-03-28 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114924073B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116449018A (zh) * | 2023-02-14 | 2023-07-18 | 浙江大学 | 一种用于肠腺瘤腺癌诊断的血浆蛋白标记物及应用 |
WO2023185709A1 (zh) * | 2022-03-28 | 2023-10-05 | 武汉迈特维尔医学科技有限公司 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060286627A1 (en) * | 2001-04-20 | 2006-12-21 | Biolog Inc. | Methods and kits for obtaining a metabolic profile of living animal cells |
US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
US20100240598A1 (en) * | 2009-03-16 | 2010-09-23 | The Regents Of The University Of California | Peptides and peptide mimetics to inhibit the onset and/or progression of fibrotic and/or pre-fibrotic pathologies |
US20170121719A1 (en) * | 2015-10-30 | 2017-05-04 | University Of Kansas | Dereplication strain of aspergillus nidulans |
CN109580948A (zh) * | 2018-11-30 | 2019-04-05 | 中国科学院上海有机化学研究所 | 基于二氢胸腺嘧啶代谢物的组合在结直肠癌诊断及预后预测中的应用 |
CN110283910A (zh) * | 2019-06-21 | 2019-09-27 | 浙江大学 | 目标基因dna甲基化作为分子标志物在制备判别结直肠组织癌变进展试剂盒中的应用 |
CN110618215A (zh) * | 2018-10-22 | 2019-12-27 | 嘉兴迈维代谢生物科技有限公司 | 一种代谢组学检测用质控品及其质控方法 |
-
2022
- 2022-03-28 CN CN202210317138.9A patent/CN114924073B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
US20060286627A1 (en) * | 2001-04-20 | 2006-12-21 | Biolog Inc. | Methods and kits for obtaining a metabolic profile of living animal cells |
US20100240598A1 (en) * | 2009-03-16 | 2010-09-23 | The Regents Of The University Of California | Peptides and peptide mimetics to inhibit the onset and/or progression of fibrotic and/or pre-fibrotic pathologies |
US20170121719A1 (en) * | 2015-10-30 | 2017-05-04 | University Of Kansas | Dereplication strain of aspergillus nidulans |
CN110618215A (zh) * | 2018-10-22 | 2019-12-27 | 嘉兴迈维代谢生物科技有限公司 | 一种代谢组学检测用质控品及其质控方法 |
CN109580948A (zh) * | 2018-11-30 | 2019-04-05 | 中国科学院上海有机化学研究所 | 基于二氢胸腺嘧啶代谢物的组合在结直肠癌诊断及预后预测中的应用 |
CN110283910A (zh) * | 2019-06-21 | 2019-09-27 | 浙江大学 | 目标基因dna甲基化作为分子标志物在制备判别结直肠组织癌变进展试剂盒中的应用 |
Non-Patent Citations (3)
Title |
---|
MEITAL B.D. BLOCH等: "The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide", 《JOURNAL OF CONTROLLED RELEASE》, pages 102 - 117 * |
傅燕芳等: "胆汁酸(盐)研究的新发现", 《国外医药——合成药、生化药、制剂分册》, vol. 13, no. 05, pages 264 - 266 * |
史祚秀等: "结直肠癌患者血浆代谢物水平研究", 《中国现代医学杂志》, vol. 30, no. 24, pages 35 - 40 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023185709A1 (zh) * | 2022-03-28 | 2023-10-05 | 武汉迈特维尔医学科技有限公司 | 结直肠进展期肿瘤诊断标志物组合及其应用 |
CN116449018A (zh) * | 2023-02-14 | 2023-07-18 | 浙江大学 | 一种用于肠腺瘤腺癌诊断的血浆蛋白标记物及应用 |
CN116449018B (zh) * | 2023-02-14 | 2023-09-05 | 浙江大学 | 一种用于肠腺瘤腺癌诊断的血浆蛋白标记物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114924073B (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10330688B2 (en) | Metabolic biomarkers of autism | |
Zhang et al. | Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry | |
Zhang et al. | Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach | |
AU2006291988B2 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites | |
CN113960215B (zh) | 用于肺腺癌诊断的标志物及其应用 | |
CN114373510B (zh) | 用于肺癌诊断或监测的代谢标志物及其筛选方法和应用 | |
CN108414660B (zh) | 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用 | |
CN114924073B (zh) | 结直肠进展期肿瘤诊断标志物组合及其应用 | |
WO2023082821A1 (zh) | 用于肺部良恶性结节诊断的血清代谢标志物及其应用 | |
BRPI0709176A2 (pt) | biomarcadores úteis para diagnosticar o cáncer de próstata e seus métodos | |
WO2011157655A1 (en) | Use of bile acids for prediction of an onset of sepsis | |
Liang et al. | Serum metabolomics uncovering specific metabolite signatures of intra-and extrahepatic cholangiocarcinoma | |
WO2017003936A1 (en) | Methods for detecting, diagnosing and treating endometrial cancer | |
CN113567585A (zh) | 一种基于外周血的食管鳞癌筛查标志物及试剂盒 | |
Zhang et al. | Altered phosphatidylcholines expression in sputum for diagnosis of non-small cell lung cancer | |
WO2023083020A1 (zh) | 血清代谢标志物作为检测egfr突变的应用以及检测系统 | |
CN109946467B (zh) | 一种用于胸椎黄韧带骨化诊断的生物标记物 | |
ES2841950T3 (es) | Un procedimiento de diagnóstico de cáncer pancreático en base al análisis lipidómico de un fluido corporal | |
CN114674969A (zh) | 尿液中生物标志物检测试剂在制备新冠肺炎诊断试剂盒中的用途 | |
CN113533560A (zh) | 基于代谢组学的食管癌早期筛查标志物及其试剂盒 | |
CN114965733B (zh) | 结直肠进展期腺瘤诊断代谢标志物组合及其应用 | |
EP4045905A1 (en) | Method of diagnosing early-stage non-small cell lung cancer | |
WO2023185709A1 (zh) | 结直肠进展期肿瘤诊断标志物组合及其应用 | |
CN116519952B (zh) | 颈动脉体瘤术前筛查及诊断的标志物及其应用 | |
CN114705782B (zh) | 用于诊断或监测结直肠癌的血浆代谢标志物组合及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230403 Address after: Room 01, 3rd Floor, Building C2-1, Building C2, C6, and C7, Wuhan National Bioindustry Base, No. 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 Applicant after: Wuhan Metville Medical Technology Co.,Ltd. Address before: 430000 No. 01, floor 2, building C2-1, Wuhan National biological industry base, No. 666, Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Applicant before: Wuhan Mai Tver Biological Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |